Outcomes of Everolimus plus Exemestane in ER-positive, HER2-negative Heavily Pre-treated Metastatic Breast Cancer Patients: A Real Life Multicentre Experience

被引：0
|
作者：
Desai, P. [1 ]
Hogg, M. [2 ]
机构：
[1] Royal Preston Hosp, Preston, Lancs, England
[2] Royal Preston Hosp, Rosemere Canc Ctr, Preston, Lancs, England
来源：
CLINICAL ONCOLOGY | 2018年 / 30卷 / 06期
关键词：
D O I：
10.1016/j.clon.2018.02.008
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E42 / E43
页数：5
相关论文
共 50 条
  • [21] Exemestane plus entinostat in HR-positive/HER2-negative breast cancer?
    Lichert, Frank
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2022, 82 (01) : 18 - 18
  • [22] Treatment Outcomes according to the EndoPredict Score in ER-Positive, HER2-Negative Early Breast Cancer
    Jung, Wonguen
    Kim, Kyubo
    Moon, Byung-In
    BREAST CARE, 2022, 17 (06) : 561 - 566
  • [23] Eribulin monotherapy improved survivals in patients with ER-positive HER2-negative metastatic breast cancer in the real world: a single institutional review
    Watanabe, Junichiro
    SPRINGERPLUS, 2015, 4
  • [24] Correction to: Unexpected Benefit from Alpelisib and Fulvestrant in a Woman with Highly Pre-treated ER-Positive, HER2-Negative PIK3CA Mutant Metastatic Breast Cancer
    Griet Hoste
    Laurence Slembrouck
    Lynn Jongen
    Kevin Punie
    Tom Matton
    Sara Vander Borght
    Isabelle Vanden Bempt
    Johan Menten
    Hans Wildiers
    Giuseppe Floris
    Carlos Arteaga
    Patrick Neven
    Clinical Drug Investigation, 2019, 39 : 113 - 113
  • [25] Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2-negative breast cancer: a randomized pilot trial
    Wei Wu
    Jiewen Chen
    Heran Deng
    Liang Jin
    Zhanghai He
    Nanyan Rao
    Yan Nie
    Yandan Yao
    Yaping Yang
    Fengxi Su
    Jieqiong Liu
    BMC Cancer, 21
  • [26] Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2-negative breast cancer: a randomized pilot trial
    Wu, Wei
    Chen, Jiewen
    Deng, Heran
    Jin, Liang
    He, Zhanghai
    Rao, Nanyan
    Nie, Yan
    Yao, Yandan
    Yang, Yaping
    Su, Fengxi
    Liu, Jieqiong
    BMC CANCER, 2021, 21 (01)
  • [27] Novel Endocrine Therapy Agents in ER-Positive, HER2-Negative Breast Cancer
    Hamilton, Erika P.
    Rugo, Hope S.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2023, 21 (03) : 125 - 127
  • [28] EFFICACY AND SAFETY OF ERIBULIN IN PATIENTS WITH HER2-NEGATIVE METASTATIC BREAST CANCER: REAL LIFE EXPERIENCE
    Zhilyaeva, Larisa
    BREAST, 2017, 36 : S53 - S54
  • [29] Fulvestrant in heavily pre-treated ER-positive post-menopausal metastatic breast cancer patients: final update of a phase II study
    Ratti, R.
    Coccorullo, Z.
    Guarneri, D.
    Addamo, G.
    Colloca, G.
    Venturino, A.
    Campora, E.
    EJC SUPPLEMENTS, 2009, 7 (02): : 279 - 279
  • [30] The impact of intratumoral heterogeneity on the prognosis of ER-positive/HER2-negative breast cancer
    Oikawa, Masahiro
    Ishida, Mayumi
    Nakamura, Yoshiaki
    Nishimura, Sumiko
    Koga, Chinami
    Saruwatari, Akihiro
    Igawa, Akiko
    Akiyoshi, Sayuri
    Koi, Yumiko
    Ohno, Shinji
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
12345